SULJE VALIKKO

Englanninkielisten kirjojen poikkeusaikata... LUE LISÄÄ

avaa valikko

R E Fidler | Akateeminen Kirjakauppa

Haullasi löytyi yhteensä 3 tuotetta
Haluatko tarkentaa hakukriteerejä?



Screening for Biological Response Modifiers: Methods and Rationale
James E. Talmadge; Isaiah J. Fidler; R.K. Oldham
Kluwer Academic Publishers (1985)
Kovakantinen kirja
97,90
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
Tucker V. Peiler U.S. Supreme Court Transcript of Record with Supporting Pleadings
R E Fidler; John P Bartlett
Gale, U.S. Supreme Court Records (2011)
Pehmeäkantinen kirja
61,50
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
Screening for Biological Response Modifiers: Methods and Rationale
James E. Talmadge; Isaiah J. Fidler; R.K. Oldham
Springer-Verlag New York Inc. (2011)
Pehmeäkantinen kirja
97,90
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
Screening for Biological Response Modifiers: Methods and Rationale
97,90 €
Kluwer Academic Publishers
Sivumäärä: 194 sivua
Asu: Kovakantinen kirja
Painos: 1985
Julkaisuvuosi: 1985, 30.04.1985 (lisätietoa)
Kieli: Englanti
Tuotesarja: Developments in Oncology 29
The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).

Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
LISÄÄ OSTOSKORIIN
Tilaustuote | Arvioimme, että tuote lähetetään meiltä noin 4-5 viikossa | Tilaa jouluksi viimeistään 27.11.2024
Myymäläsaatavuus
Helsinki
Tapiola
Turku
Tampere
Screening for Biological Response Modifiers: Methods and Rationale
Näytä kaikki tuotetiedot
ISBN:
9780898387124
Sisäänkirjautuminen
Kirjaudu sisään
Rekisteröityminen
Oma tili
Omat tiedot
Omat tilaukset
Omat laskut
Lisätietoja
Asiakaspalvelu
Tietoa verkkokaupasta
Toimitusehdot
Tietosuojaseloste